Results 51 to 60 of about 2,196 (157)

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats [PDF]

Journal of Lipid Research, 2010
High density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) reduce inflammatory responses to lipopolysaccharide (LPS). We tested the hypothesis that the apoA-I mimetic peptide 4F prevents LPS-induced defects in blood pressure and vascular reactivity. Systolic blood pressure (SBP) was measured in rats at baseline and 6 h after injection of LPS (10 mg/
Lijun Dai, Geeta Datta, Zhenghao Zhang, Himanshu Gupta, Rakesh Patel, Jaideep Honavar, Sarika Modi, J. Michael Wyss, Mayakonda Palgunachari, G.M. Anantharamaiah, C. Roger White   +10 more
openaire   +3 more sources

Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis

Journal of Lipid Research, 2015
We previously reported that i) a Western diet increased levels of unsaturated lysophosphatidic acid (LPA) in small intestine and plasma of LDL receptor null (LDLR−/−) mice, and ii) supplementing standard mouse chow with unsaturated (but not saturated ...
Mohamad Navab, Arnab Chattopadhyay, Greg Hough, David Meriwether, Spencer I. Fogelman, Alan C. Wagner, Victor Grijalva, Feng Su, G.M. Anantharamaiah, Lin H. Hwang, Kym F. Faull, Srinivasa T. Reddy, Alan M. Fogelman   +12 more
doaj   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
Objectives— The apolipoprotein (apo)A-I mimetic peptide 5A is highly specific for ATP-binding cassette transporter (ABC)A1-mediated cholesterol efflux. We investigated whether the 5A peptide shares other beneficial features of apoA-I, such as protection against inflammation and oxidation.
Fatiha, Tabet, Alan T, Remaley, Aude I, Segaliny, Jonathan, Millet, Ling, Yan, Shirley, Nakhla, Philip J, Barter, Kerry-Anne, Rye, Gilles, Lambert   +8 more
openaire   +2 more sources

Synthetic apolipoprotein A-I mimetic peptide 4F protects hearts and kidneys after myocardial infarction [PDF]

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2020
Patients undergoing coronary angiography after myocardial infarction (MI) often develop cardiac and renal dysfunction. We hypothesized that the apolipoprotein A-I mimetic peptide 4F (4F) would prevent those complications. Male Wistar rats were fed a high-cholesterol diet for 8 days.
Roberto S. Moreira, Maria C. Irigoyen, Jose M. C. Capcha, Talita R. Sanches, Paulo S. Gutierrez, Margoth R. Garnica, Irene de L. Noronha, Lucia Andrade   +7 more
openaire   +2 more sources

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Oxidized phospholipids cause changes in jejunum mucus that induce dysbiosis and systemic inflammation

Journal of Lipid Research, 2022
We previously reported that adding a concentrate of transgenic tomatoes expressing the apoA-I mimetic peptide 6F (Tg6F) to a Western diet (WD) ameliorated systemic inflammation.
Pallavi Mukherjee, Arnab Chattopadhyay, Victor Grijalva, Nasrin Dorreh, Venu Lagishetty, Jonathan P. Jacobs, Bethan L. Clifford, Thomas Vallim, Julia J. Mack, Mohamad Navab, Srinivasa T. Reddy, Alan M. Fogelman   +11 more
doaj   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, Volume 6, Issue 8, August 2026.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Apolipoprotein A‐I mimetic peptide L‐4F prevents myocardial and coronary dysfunction in diabetic mice [PDF]

Journal of Cellular Biochemistry, 2011
Abstract Diabetes is a major health problem associated with adverse cardiovascular outcomes. The apolipoprotein A‐I mimetic peptide L‐4F is a putative anti‐diabetic drug, has antioxidant and anti‐inflammatory proprieties and improves endothelial function.
Vecoli C, Cao J, Neglia D, Inoue K, Sodhi K, VANELLA, LUCA, Gabrielson K. K, Bedja D, Paolocci N, L'abbate A, Abraham N. G.   +10 more
openaire   +6 more sources